CUSIP: 829399104
Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COMMON
-
Total 13F shares
-
20,679,712
-
Share change
-
+2,579,420
-
Total reported value
-
$8,528,467
-
Put/Call ratio
-
0%
-
Price per share
-
$0.36
-
Number of holders
-
29
-
Value change
-
+$1,692,078
-
Number of buys
-
11
-
Number of sells
-
20
Quarterly Holders Quick Answers
What is CUSIP 829399104?
CUSIP 829399104 identifies SIOX - SIO GENE THERAPIES INC - COMMON in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2022
-
Previous quarter:
Q1 2022
Recent filing periods for CUSIP 829399104:
Institutional Holders of SIO GENE THERAPIES INC - COMMON (SIOX) as of Q2 2022
As of 30 Jun 2022,
SIO GENE THERAPIES INC - COMMON (SIOX) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,679,712 shares.
The largest 10 holders included
Rubric Capital Management LP, SUVRETTA CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, Hudson Bay Capital Management LP, Newtyn Management, LLC, Cladis Investment Advisory, LLC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, Clearline Capital LP, and BlackRock Inc..
This page lists
29
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.